How Does Cyclosporine Work? Mechanism of Action, Per the Research

Cyclosporine (ciclosporin, cyclosporin A) is a cyclic eleven–amino-acid fungal peptide used as a prescription immunosuppressant. It is not a supplement and is available only within a prescription relationship. This page summarises what the published pharmacology literature reports about how the molecule works at a molecular level. It does not discuss dosing, does not recommend use, and makes no claim about outcomes in any individual.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including whether cyclosporine is appropriate, and never start or change a prescription based on a web page.

The Short Version of the Mechanism

The established mechanism has three sequential steps described across the pharmacology literature:

1. Cyclosporine enters the cell and binds cyclophilin. A review of immunophilin structures, mechanisms and ligands described cyclophilins as peptidyl-prolyl isomerase enzymes that act as the intracellular receptors for cyclosporine, with FK506-binding proteins serving the analogous role for tacrolimus (PMID 25986569).
2. The cyclosporine–cyclophilin complex inhibits calcineurin. That same immunophilin review reported that the drug–immunophilin complex, rather than either partner alone, is the species that engages and inhibits the phosphatase calcineurin (PMID 25986569).
3. NFAT stays phosphorylated and stays out of the nucleus. A review of the calcium–calcineurin–NFAT pathway in health and autoimmune disease described calcineurin as the calcium/calmodulin-dependent phosphatase that dephosphorylates NFAT transcription factors to permit their nuclear translocation and transcription of cytokine genes (PMID 32210952).

In plain terms: the drug jams a switch that converts a calcium signal at the T-cell receptor into cytokine gene transcription. The literature frames this as the reason cyclosporine is described as a calcineurin inhibitor.

Step One: Cyclophilin, the Intracellular Receptor

Cyclosporine does not act on a cell-surface receptor in the way a hormone-like peptide does. The immunophilin review characterised cyclophilins as abundant intracellular proteins with peptidyl-prolyl cis-trans isomerase activity, and described cyclosporine as a ligand that binds them (PMID 25986569). An important nuance from that review is that inhibiting the isomerase activity itself is not the immunosuppressive event — the pharmacologically relevant product is the composite surface formed by drug plus immunophilin (PMID 25986569).

A chemistry and toxicity review of cyclosporine A described the molecule as a lipophilic cyclic peptide and discussed how its physicochemical properties and metabolism relate to its biological and toxicological profile (PMID 33023428). Lipophilicity matters mechanistically because the target is intracellular: the compound has to cross the plasma membrane before anything downstream can happen.

Step Two: Calcineurin, the Calcium-Activated Phosphatase

Calcineurin is the convergence point. The calcium–calcineurin–NFAT review described the pathway as activated when receptor engagement raises intracellular calcium, calcium binds calmodulin, and the calcium/calmodulin complex activates calcineurin (PMID 32210952). The same review discussed the pathway's involvement in immune cell function and in autoimmune disease biology (PMID 32210952).

Calcineurin is not an immune-only enzyme, which is central to understanding why calcineurin inhibitors have effects beyond lymphocytes. A review of calcineurin signalling during development described roles for the phosphatase in neural development and in tissues outside the immune system, and discussed the consequences of modulating that signalling (PMID 35785416). That breadth of substrate is the mechanistic explanation most often offered in the literature for why an immunosuppressant produces renal and neurological effects as well.

Why "calcineurin inhibitor" is a class label

Both cyclosporine and tacrolimus converge on calcineurin despite binding different immunophilins; the immunophilin review set out cyclophilin versus FKBP as the distinguishing upstream step with a shared downstream target (PMID 25986569). This is why the two drugs share a mechanistic class name while differing in chemistry.

Step Three: NFAT and Downstream Transcription

NFAT is the transcription factor family that carries the signal into the nucleus. The calcium–calcineurin–NFAT review described calcineurin-dependent dephosphorylation as the event that unmasks NFAT's nuclear localisation signal and allows cytokine gene transcription to proceed (PMID 32210952).

NFAT biology is not confined to T cells. A review of NFAT control of innate immunity described NFAT signalling in innate immune cell populations and its contribution to innate immune gene programmes (PMID 22611159). That review is often cited as evidence that calcineurin inhibition plausibly touches more than adaptive immunity (PMID 22611159).

Mechanism at a glance

A Second, Separable Mechanism: Mitochondria

Not every proposed action of cyclosporine runs through calcineurin. A review of cyclosporine as therapy for traumatic brain injury described the compound's interaction with mitochondrial cyclophilin D and the mitochondrial permeability transition pore as a mechanism distinct from immunosuppression, and discussed its investigation in neurotrauma on that basis (PMID 37561274). This is the clearest example in the verified literature of mechanism being separated into established immunological action versus proposed non-immunological action under study; that review framed the neurotrauma application as a research question rather than settled practice (PMID 37561274).

Readers should treat the mitochondrial pathway as mechanistically described but not as an approved indication. Whether any of it translates into clinical benefit is a question for trial evidence and regulators, not for mechanism diagrams.

How Mechanism Connects to Inflammatory Skin Disease

Calcineurin inhibition is invoked to explain cyclosporine's use in T-cell-driven inflammatory disease. Transcriptomic work in atopic dermatitis reported stable and dynamic skin transcriptome signatures across lesional and non-lesional skin, characterising the inflammatory gene programmes present in the disease (PMID 32615169). A separate review of dupilumab in atopic dermatitis discussed systemic treatment of the condition and the place of targeted biologic therapy in that landscape (PMID 29557246). Comparing a broad calcineurin inhibitor with a cytokine-specific antibody is the usual way the literature illustrates the difference between upstream, non-selective immunosuppression and narrow pathway blockade (PMID 29557246).

Veterinary pharmacology provides another mechanistic illustration. A report on medical management of canine chronic ulcerative stomatitis described the use of cyclosporine with metronidazole in that condition in dogs (PMID 36650996). Animal clinical reports are labelled as such here: they describe veterinary practice, not human dosing or human outcomes.

Adverse Effects of the Mechanism: What Studies Report

Because calcineurin and NFAT operate outside lymphocytes, the pharmacology literature links several toxicities back to the same mechanism.

• Kidney. A review of cyclosporine nephrotoxicity described acute, haemodynamically mediated renal effects and chronic structural renal injury as recognised consequences of calcineurin inhibitor therapy (PMID 13680536). That review treated nephrotoxicity as a defining limitation of the drug class (PMID 13680536).
• Nervous system. A review of biochemical mechanisms of cyclosporine neurotoxicity discussed proposed cellular pathways by which the drug produces neurological adverse effects (PMID 15087483). Consistent with calcineurin's non-immune roles, the developmental calcineurin review described signalling functions in neural tissue (PMID 35785416).
• Pain syndromes. A clinical report described cyclosporine-induced erythromelalgia, a painful erythematous extremity syndrome attributed to the drug (PMID 37391230).
• General toxicology. The chemistry and toxicity review surveyed the toxicological profile of cyclosporine A alongside its chemistry (PMID 33023428).

None of this is a complete safety list, and nothing here predicts what would happen in any individual. Monitoring requirements, drug interactions and contraindications for a prescription immunosuppressant are decided by the prescribing clinician.

Established Mechanism Versus Proposed Mechanism

A fair reading of the verified literature separates the two:

• Established: cyclophilin binding, formation of an inhibitory complex with calcineurin, and consequent blockade of NFAT dephosphorylation and nuclear translocation (PMID 25986569, PMID 32210952).
• Described but broader than classically taught: NFAT activity in innate immune cells, suggesting effects beyond T-cell cytokine transcription (PMID 22611159).
• Proposed and under investigation: mitochondrial permeability transition pore inhibition via cyclophilin D as a neuroprotective mechanism in traumatic brain injury (PMID 37561274).

What a Mechanism Page Cannot Tell You

Knowing that a drug inhibits calcineurin says nothing about whether it is appropriate for a given person, how it is monitored, or how it interacts with other medicines. Cyclosporine is a prescription product whose approved indications, labelling and monitoring requirements are set by regulators and interpreted by clinicians. Researchers describing nephrotoxicity framed it as a therapy-limiting problem in its own right (PMID 13680536), which is exactly why the same mechanism that produces an immunological effect also demands clinical supervision. Any question about whether, when or how this medicine might be used belongs with a licensed prescriber.

References

• Immunophilins: Structures, Mechanisms and Ligands (Current Molecular Pharmacology, 2015)
• The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases (Frontiers in Immunology, 2020)
• NFAT control of innate immunity (Blood, 2012)
• Modulation of calcineurin signaling during development (Developmental Neurobiology, 2022)
• Cyclosporine A: Chemistry and Toxicity - A Review (Current Medicinal Chemistry, 2021)
• Cyclosporine as Therapy for Traumatic Brain Injury (Neurotherapeutics, 2023)
• Cyclosporine nephrotoxicity (Seminars in Nephrology, 2003)
• Biochemical mechanisms of cyclosporine neurotoxicity (Molecular Interventions, 2004)
• Cyclosporine-induced erythromelalgia (Practical Neurology, 2023)
• Atopic dermatitis displays stable and dynamic skin transcriptome signatures (Journal of Allergy and Clinical Immunology, 2021)
• Dupilumab for treatment of atopic dermatitis (Expert Review of Clinical Pharmacology, 2018)
• Medical Management of Canine Chronic Ulcerative Stomatitis Using Cyclosporine and Metronidazole (Journal of Veterinary Dentistry, 2023)